Evidence map›Paper›PMID 32216548›Full record

ArticleThyroid : official journal of the American Thyroid Association2020

Acquired Secondary RAS Mutation in BRAF

Maria E Cabanillas, Ramona Dadu, Pryianka Iyer, Kacey B Wanland, Naifa L Busaidy, Anita Ying, Maria Gule-Monroe, Jennifer R Wang, Mark Zafereo, Marie-Claude Hofmann

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure.Thyroid : official journal of the American Thyroid Association · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ramona DaduDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pryianka IyerDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kacey B WanlandDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naifa L BusaidyDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anita YingDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria Gule-MonroeDepartment of Diagnostic Radiology, and The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer R WangDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mark ZafereoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marie-Claude HofmannDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2013 to 2017
$10.9M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA168505
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mutation, MissenseData CollectionDisease ProgressionGenes, rasHumansImmunotherapyLiquid BiopsyMaleMiddle AgedMutationPositron Emission Tomography Computed TomographyProtein Kinase InhibitorsProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafanaplastic thyroid cancerclonal divergencedabrafenibdifferentiated thyroid cancerdrug resistancegenetic mutationskinase inhibitorsmolecular testingmutational pathwayspapillary thyroid cancer

Identifiers

PMID32216548
PMCPMC7869871
OpenAlexW3013546523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.